11A
BMY.RT

10-15 Associates’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

10-15 Associates’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-21,457
Closed -$77K – 102
2020
Q2 		$77K Sell
21,457
-100
-0.5% -$361 0.02% 95
2020
Q1 		$82K Sell
21,557
-250
-1% -$824 0.02% 89
2019
Q4 		$66K Buy
+21,807
New +$56.7K 0.01% 99

Other funds holding BMY.RT

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

10-15 Associates's BMY.RT Position: Q3 2020 in Review

10-15 Associates sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q3 2020, closing a stake of 21,457 shares — an estimated $77K sold.

10-15 Associates first reported a position in BMY.RT in Q4 2019 and held it in 3 quarters. The position peaked at $82K in Q1 2020. 571 funds tracked by Wall St. Rank hold BMY.RT as of Q3 2020.

  • 10-15 Associates reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q3 2020 after selling out during the quarter.
  • 10-15 Associates sold 21,457 Bristol-Myers Squibb Company Contingent Value Rights shares in Q3 2020, an estimated $77K.
  • 10-15 Associates first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 3 quarters.
  • 10-15 Associates's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $82K in Q1 2020.
  • 571 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q3 2020.

Based on 10-15 Associates's 13F filing for Q3 2020, filed 13 Oct 2020.